search
Back to results

The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence

Primary Purpose

Twin Anemia Polycythemia Sequence

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Fetoscopic Laser Surgery
Standard Treatment
Sponsored by
Leiden University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Twin Anemia Polycythemia Sequence focused on measuring Monochorionic Twins, Twin-Twin Transfusion Syndrome, Fetoscopic Laser Surgery, Intrauterine Transfusion, Partial Exchange Transfusion

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Monochorionic twin pregnancy complicated by either spontaneous or post-laser twin anemia polycythemia sequence (TAPS), stage ≥ 2, diagnosed between 20+0 and till 28+0 weeks of gestation
  • Women aged 18 years or more, who are able to consent.
  • Written informed consent to participate in this randomized controlled trial, forms being approved by the Ethical Committees.

Exclusion Criteria:

  • TAPS stage 1
  • TAPS stage≥ 2, diagnosed within 1 week after laser surgery for twin-twin transfusion syndrome (TTTS) (a large inter-twin middle cerebral artery peak systolic velocity difference within a week after laser for TTTS is likely to related to hemodynamic reequilibration, and is usually not based on TAPS)
  • Triplet pregnancies, or higher order multiple pregnancies
  • TAPS cases that already underwent an intrauterine treatment (with the exception of laser surgery for TTTS in post-laser TAPS cases)
  • Congenital abnormalities (including severe cerebral injury) in one or both twins

Sites / Locations

  • Yale University
  • Vittore Buzzi Children's HospitalRecruiting
  • Leiden University Medical CenterRecruiting
  • Vall d'Hebron University HospitalRecruiting
  • Karolinska University Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

Fetoscopic Laser Surgery

Standard Treatment

Arm Description

fetoscopic laser coagulation of the vascular anastomoses at the placental surface

Expectant management, IUT (with or without PET), preterm delivery

Outcomes

Primary Outcome Measures

Gestational Age at Birth
Gestational age: completed weeks + additional days since the first day of the last menstruational period of the mother.

Secondary Outcome Measures

Number of patients with perinatal mortality
Perinatal mortality is defined as fetal death or neonatal death (demise of a liveborn child within 28 days after birth)
Number of patients with severe neonatal morbidity
Severe neonatal morbidity is defined as the presence of at least one of the following: Respiratory distress syndrome requiring surfactant or mechanical ventilation Proven early onset neonatal sepsis with positive blood cultures within 72 hours postpartum Retinopathy of prematurity stage 3 or higher Necrotizing enterocolitis stage 2 or higher Patent ductus arteriosus requiring medical therapy or surgical closure Severe cerebral injury (defined as intraventricular hemorrhage grade 3 or higher, cystic periventricular leukomalacia grade 2 or higher, ventricular dilatation greater than the 97th centile, porencephalic or parenchymal cysts or other severe cerebral lesions)
Number of patients with hematological complications
Hematological complications are defined as the presence of at least one of the following: Anemia in donor requiring a blood transfusion within 24 hours after birth Polycythemia in recipient requiring a partial exchange transfusion within 24 hours after birth necrotic skin injury limb ischemia platelet count < 150,000/microL albumin levels < 20 g/L protein levels < 40 g/L
Number of patients with procedure-related complications
Procedure-related complications are defined as at least one of the following: amniotic band syndrome iatrogenic monoamnionicity Preterm premature rupture of the membranes Placental abruption clinical chorioamnionitis histological chorioamnionitis and/or funisitis
Number of patient with mild neurodevelopmental impairment
Mild neurodevelopmental impairment is defined as at least one of the following: cerebral palsy (spastic bilateral, spastic unilateral, or mixed) Impaired cognitive or motor development defined as Score < 85 (1 standard deviation (SD) below the mean) as assessed by Bayley Scales of Infant and Toddler Development version 3 (BSID-III) Impaired functioning in communication, fine and gross motor, problem solving, personal and social functioning defined as Score > 1 SD below the mean as assessed by Ages and Stages Questionnaire version 3 (ASQ-III) severe visual loss (blind or partially sighted) severe hearing loss (needing hearing aids)
Number of patients with severe neurodevelopmental impairment
Severe neurodevelopmental impairment is defined as at least one of the following: cerebral palsy defined as a gross motor function classification system (CMFCS) grade > 1 Impaired cognitive or motor development defined as a score < 70 (2 SD below the mean) as assessed by the Bayley Scales of Infant and Toddler Development version 3 (BSID-III) Impaired functioning in communication, fine and gross motor, problem solving, personal and social functioning defined as a score > 2 SD below the mean as assessed by Ages and Stages Questionnaire version 3 (ASQ-III) Bilateral blindness defined as visual acuity of less than 3/60 in the better eye Bilateral deafness defined as severe or profound hearing loss in both ears (severe hearing loss: a person can only hear sounds > 70-89 decibel , profound hearing loss: a person can only hear sounds > 90 decibel
Number of patients with behavioral problems
Behavioral problems are defined as a T-score ≥ 64 for one of the following broad band scales: total problem score, Internalizing problems (anxious/depressed, withdrawn, somatic complaints), Externalizing problems (rule-breaking, aggressive behavior) as measured with the Child Behaviour Checklist 1.5-5 years

Full Information

First Posted
May 11, 2020
Last Updated
June 11, 2020
Sponsor
Leiden University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04432168
Brief Title
The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence
Official Title
The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia-Polycythemia Sequence - a Multicenter Open-Label Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Recruiting
Study Start Date
April 30, 2019 (Actual)
Primary Completion Date
April 30, 2022 (Anticipated)
Study Completion Date
April 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Leiden University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This multicenter open-label randomized controlled trial is set up to evaluate the effect of fetoscopic laser surgery on the gestational age at birth for monochorionic twin pregnancies diagnosed with twin anemia-polycythemia sequence. Half op the patients will be treated with fetoscopic laser surgery, while the other half will be managed with standard treatment. The hypothesis is that fetoscopic laser therapy will improve neonatal outcome by prolonging pregnancy.
Detailed Description
Rationale: Monochorionic twins share one placenta and are connected to each other via vascular anastomoses at the placental surface, allowing the blood to transfer bi-directionally between the two fetuses. Unbalanced inter-twin blood transfusion can result in twin anemia-polycythemia sequence (TAPS). Management options include: fetoscopic laser surgery, intrauterine blood transfusion (IUT) with or without partial exchange transfusion (PET), preterm delivery, selective feticide and expectant management. The optimal treatment for TAPS is not clear. Fetoscopic laser surgery is the only causative treatment option, but data on the feasibility of this procedure are mainly based on case reports and small cohort studies. A large randomized controlled trial is needed to evaluate the possible beneficial effect of fetoscopic laser surgery and to determine the optimal treatment option for TAPS. Objective: The aim of this trial is to investigate whether fetoscopic laser surgery improves the outcome for TAPS twins as compared to the control group (standard care consisting of expectant management, IUT, preterm delivery). The hypothesis is that fetoscopic laser therapy will improve neonatal outcome by prolonging pregnancy. Study design: International multi-centered open-label randomized controlled trial to assess whether fetoscopic laser surgery (experimental group) improves the outcome of TAPS twins compared to standard care (control group). Study population: Monochorionic twin pregnancies with TAPS stage ≥ 2 (spontaneous or post-laser) diagnosed between 20 and 28 weeks of gestation. Intervention: In the experimental group fetoscopic laser surgery is performed, whereas the control group is treated with standard care (expectant management, IUT (with PET), selective feticide and/or preterm delivery, depending on the opinion of the fetal surgeon). Main study endpoints: The primary outcome is gestational age at birth. Secondary outcomes include: perinatal mortality or severe neonatal morbidity, hematological complication, procedure related complications and long-term neurodevelopmental outcome at 2 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Twin Anemia Polycythemia Sequence
Keywords
Monochorionic Twins, Twin-Twin Transfusion Syndrome, Fetoscopic Laser Surgery, Intrauterine Transfusion, Partial Exchange Transfusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fetoscopic Laser Surgery
Arm Type
Experimental
Arm Description
fetoscopic laser coagulation of the vascular anastomoses at the placental surface
Arm Title
Standard Treatment
Arm Type
Other
Arm Description
Expectant management, IUT (with or without PET), preterm delivery
Intervention Type
Procedure
Intervention Name(s)
Fetoscopic Laser Surgery
Other Intervention Name(s)
Fetoscopic Laser Coagulation, Laser therapy, Fetoscopic Laser Ablation
Intervention Description
Fetoscopic Photocoagulation of the connecting vascular anastomoses on the surface of the placenta.
Intervention Type
Other
Intervention Name(s)
Standard Treatment
Intervention Description
In the control group, the choices of treatment include expectant management, intrauterine transfusion (IUT) (with or without partial exchange transfusion (PET)) or preterm delivery, depending on the judgment of the fetal surgeon with regard to the gestational age and state of the disease. Expectant management will consist of close monitoring with ultrasound including Doppler measurements of the middle cerebral artery peak systolic velocity (MCA-PSV), at least every week. IUT: the intrauterine infusion of red blood cells into the circulation of the donor twin treat anemia. PET: the intrauterine infusion of saline into the circulation of the recipient twin to treat polycythemia. Preterm delivery: Induction of labor or cesarean section before 36 weeks of gestation.
Primary Outcome Measure Information:
Title
Gestational Age at Birth
Description
Gestational age: completed weeks + additional days since the first day of the last menstruational period of the mother.
Time Frame
2 weeks after expected date of birth
Secondary Outcome Measure Information:
Title
Number of patients with perinatal mortality
Description
Perinatal mortality is defined as fetal death or neonatal death (demise of a liveborn child within 28 days after birth)
Time Frame
42 days (28 days neonatal period+2 weeks postdates) after expected date of birth
Title
Number of patients with severe neonatal morbidity
Description
Severe neonatal morbidity is defined as the presence of at least one of the following: Respiratory distress syndrome requiring surfactant or mechanical ventilation Proven early onset neonatal sepsis with positive blood cultures within 72 hours postpartum Retinopathy of prematurity stage 3 or higher Necrotizing enterocolitis stage 2 or higher Patent ductus arteriosus requiring medical therapy or surgical closure Severe cerebral injury (defined as intraventricular hemorrhage grade 3 or higher, cystic periventricular leukomalacia grade 2 or higher, ventricular dilatation greater than the 97th centile, porencephalic or parenchymal cysts or other severe cerebral lesions)
Time Frame
42 days (28 days neonatal period+2 weeks postdates) after expected date of birth
Title
Number of patients with hematological complications
Description
Hematological complications are defined as the presence of at least one of the following: Anemia in donor requiring a blood transfusion within 24 hours after birth Polycythemia in recipient requiring a partial exchange transfusion within 24 hours after birth necrotic skin injury limb ischemia platelet count < 150,000/microL albumin levels < 20 g/L protein levels < 40 g/L
Time Frame
2 weeks after expected date of birth
Title
Number of patients with procedure-related complications
Description
Procedure-related complications are defined as at least one of the following: amniotic band syndrome iatrogenic monoamnionicity Preterm premature rupture of the membranes Placental abruption clinical chorioamnionitis histological chorioamnionitis and/or funisitis
Time Frame
2 weeks after expected date of birth
Title
Number of patient with mild neurodevelopmental impairment
Description
Mild neurodevelopmental impairment is defined as at least one of the following: cerebral palsy (spastic bilateral, spastic unilateral, or mixed) Impaired cognitive or motor development defined as Score < 85 (1 standard deviation (SD) below the mean) as assessed by Bayley Scales of Infant and Toddler Development version 3 (BSID-III) Impaired functioning in communication, fine and gross motor, problem solving, personal and social functioning defined as Score > 1 SD below the mean as assessed by Ages and Stages Questionnaire version 3 (ASQ-III) severe visual loss (blind or partially sighted) severe hearing loss (needing hearing aids)
Time Frame
2 years after expected date of birth
Title
Number of patients with severe neurodevelopmental impairment
Description
Severe neurodevelopmental impairment is defined as at least one of the following: cerebral palsy defined as a gross motor function classification system (CMFCS) grade > 1 Impaired cognitive or motor development defined as a score < 70 (2 SD below the mean) as assessed by the Bayley Scales of Infant and Toddler Development version 3 (BSID-III) Impaired functioning in communication, fine and gross motor, problem solving, personal and social functioning defined as a score > 2 SD below the mean as assessed by Ages and Stages Questionnaire version 3 (ASQ-III) Bilateral blindness defined as visual acuity of less than 3/60 in the better eye Bilateral deafness defined as severe or profound hearing loss in both ears (severe hearing loss: a person can only hear sounds > 70-89 decibel , profound hearing loss: a person can only hear sounds > 90 decibel
Time Frame
2 years after expected date of birth
Title
Number of patients with behavioral problems
Description
Behavioral problems are defined as a T-score ≥ 64 for one of the following broad band scales: total problem score, Internalizing problems (anxious/depressed, withdrawn, somatic complaints), Externalizing problems (rule-breaking, aggressive behavior) as measured with the Child Behaviour Checklist 1.5-5 years
Time Frame
2 years after expected date of birth

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Monochorionic twin pregnancy complicated by either spontaneous or post-laser twin anemia polycythemia sequence (TAPS), stage ≥ 2, diagnosed between 20+0 and till 28+0 weeks of gestation Women aged 18 years or more, who are able to consent. Written informed consent to participate in this randomized controlled trial, forms being approved by the Ethical Committees. Exclusion Criteria: TAPS stage 1 TAPS stage≥ 2, diagnosed within 1 week after laser surgery for twin-twin transfusion syndrome (TTTS) (a large inter-twin middle cerebral artery peak systolic velocity difference within a week after laser for TTTS is likely to related to hemodynamic reequilibration, and is usually not based on TAPS) Triplet pregnancies, or higher order multiple pregnancies TAPS cases that already underwent an intrauterine treatment (with the exception of laser surgery for TTTS in post-laser TAPS cases) Congenital abnormalities (including severe cerebral injury) in one or both twins
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Femke Slaghekke, MD PhD
Phone
+31 71 52 97211
Email
f.slaghekke@lumc.nl
First Name & Middle Initial & Last Name or Official Title & Degree
Lisanne Tollenaar, BSc
Phone
+31653413875
Email
l.s.a.tollenaar@lumc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dick Oepkes, MD PhD
Organizational Affiliation
Leiden University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Yale University
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
208327
Country
United States
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ozan Bahtiyar, MD PhD
First Name & Middle Initial & Last Name & Degree
Ozan Bahtiyar, MD PhD
Facility Name
Vittore Buzzi Children's Hospital
City
Milan
State/Province
Lombardy
ZIP/Postal Code
20154
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariano Lanna, MD PhD
Email
info@terapiafetale.it
First Name & Middle Initial & Last Name & Degree
Mariano Lanna, MD PhD
Facility Name
Leiden University Medical Center
City
Leiden
State/Province
South-Holland
ZIP/Postal Code
2333ZA
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dick Oepkes, MD PhD
Phone
+31715261688
Email
d.oepkes@lumc.nl
First Name & Middle Initial & Last Name & Degree
Femke Slaghekke, MD PhD
Phone
+31715297211
Email
f.slaghekke@lumc.nl
First Name & Middle Initial & Last Name & Degree
Dick Oepkes, MD PhD
First Name & Middle Initial & Last Name & Degree
Enrico Lopriore, MD PhD
First Name & Middle Initial & Last Name & Degree
Femke Slaghekke, MD PhD
First Name & Middle Initial & Last Name & Degree
Lisanne Tollenaar, BSc
Facility Name
Vall d'Hebron University Hospital
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carlota Rodo, MD PhD
Email
crodo@vhebron.net
First Name & Middle Initial & Last Name & Degree
Silivia Arevalo, MD PhD
Email
siareval@vhebron.net
First Name & Middle Initial & Last Name & Degree
Carlota Rodo, MD PhD
First Name & Middle Initial & Last Name & Degree
Silivia Arevalo, MD PhD
First Name & Middle Initial & Last Name & Degree
Pablo Garcia-Manau, MD PhD
Facility Name
Karolinska University Hospital
City
Stockholm
State/Province
Södermanland
ZIP/Postal Code
141 86
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lotta Herling, MD PhD
Email
lotta.herling@sll.se
First Name & Middle Initial & Last Name & Degree
Lotta Herling, MD PhD

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
16516289
Citation
Lopriore E, Middeldorp JM, Oepkes D, Kanhai HH, Walther FJ, Vandenbussche FP. Twin anemia-polycythemia sequence in two monochorionic twin pairs without oligo-polyhydramnios sequence. Placenta. 2007 Jan;28(1):47-51. doi: 10.1016/j.placenta.2006.01.010. Epub 2006 Mar 3.
Results Reference
background
PubMed Identifier
16522415
Citation
Robyr R, Lewi L, Salomon LJ, Yamamoto M, Bernard JP, Deprest J, Ville Y. Prevalence and management of late fetal complications following successful selective laser coagulation of chorionic plate anastomoses in twin-to-twin transfusion syndrome. Am J Obstet Gynecol. 2006 Mar;194(3):796-803. doi: 10.1016/j.ajog.2005.08.069.
Results Reference
background
PubMed Identifier
25790745
Citation
Sananes N, Veujoz M, Severac F, Barthoulot M, Meyer N, Weingertner AS, Kohler M, Guerra F, Gaudineau A, Nisand I, Favre R. Evaluation of the Utility of in utero Treatment of Twin Anemia-Polycythemia Sequence. Fetal Diagn Ther. 2015;38(3):170-8. doi: 10.1159/000380822. Epub 2015 Mar 17.
Results Reference
background
PubMed Identifier
24706478
Citation
Slaghekke F, Favre R, Peeters SH, Middeldorp JM, Weingertner AS, van Zwet EW, Klumper FJ, Oepkes D, Lopriore E. Laser surgery as a management option for twin anemia-polycythemia sequence. Ultrasound Obstet Gynecol. 2014 Sep;44(3):304-10. doi: 10.1002/uog.13382. Epub 2014 Aug 4.
Results Reference
background

Learn more about this trial

The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence

We'll reach out to this number within 24 hrs